A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; IMC C103C (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Immunocore
- 09 Dec 2019 According to an Immunocore media release, the first patient has been dosed in this trial.
- 31 May 2019 Status changed from planning to recruiting.
- 03 Dec 2018 New trial record